|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ulusoy S, Akbayir O, Numanoglu C, Ulusoy
N, Odabas E and Gulkilik A: The risk of malignancy index in
discrimination of adnexal masses. Int J Gynaecol Obstet.
96:186–191. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Menon U, Talaat A, Rosenthal AN, Macdonald
ND, Jeyerajah AR, Skates SJ, Sibley K, Oram DH and Jacobs IJ:
Performance of ultrasound as a second line test to serum CA125 in
ovarian cancer screening. BJOG. 121:35–39. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Schelling M, Braun M, Kuhn W, Bogner G,
Gruber R, Gnirs J, Schneider KT, Ulm K, Rutke S and Staudach A:
Combined transvaginal B-mode and color Doppler sonography for
differential diagnosis of ovarian tumors: Results of a multivariate
logistic regression analysis. Gynecol Oncol. 77:78–86. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Goldberger S, Tepper R, Markov S and Beyth
Y: Transvaginal sonographic characterization of ovarian disease:
Evaluation of a new scoring system to predict ovarian malignancy.
Obstet Gynecol. 78:1151–1152. 1991.PubMed/NCBI
|
|
6
|
Kupesic S and Kurjak A: Contrast-enhanced,
three-dimensional power Doppler sonography for differentiation of
adnexal masses. Obstet Gynecol. 96:452–458. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Benjapibal M, Sunsaneevitayakul P,
Boriboonhirunsarn D, Sutanthavibul A and Chakorngowit M: Color
Doppler ultraso-nography for prediction of malignant ovarian
tumors. J Med Assoc Thai. 85:709–715. 2002.PubMed/NCBI
|
|
8
|
Sawicki W, Spiewankiewicz B, Cendrowski K
and Stelmachów J: Preoperative discrimination between malignant and
benign adnexal masses with transvaginal ultrasonography and colour
blood flow imaging. Eur J Gynaecol Oncol. 22:137–142.
2001.PubMed/NCBI
|
|
9
|
kurjak A, Kupesic S, Sparac V, Prka M and
Bekavac I: The detection of stage I ovarian cancer by
three-dimensional sonography and power Doppler. Gynecol Oncol.
90:258–264. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Fishman DA, Cohen L, Blank SV, Shulman L,
Singh D, Bozorgi K, Tamura R, Timor-Tritsch I and Schwartz PE: The
role of ultrasound evaluation in the detection of early-stage
epithelial ovarian cancer. Am J Obstet Gynecol. 192:1214–1221,
discussion 1221-1222. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Gupta KK, Gupta VK and Naumann RW: Ovarian
cancer: Screening and future directions. Int J Gynecol Cancer.
29:195–200. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yang Z, Zhao B and Li L: The significance
of the change pattern of serum CA125 level for judging prognosis
and diagnosing recurrences of epithelial ovarian cancer. J Ovarian
Res. 9:572016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Schummer M, Drescher C, Forrest R, Gough
S, Thorpe J, Hellström I, Hellström KE and Urban N: Evaluation of
ovarian cancer remission markers HE4, MMP7 and Mesothelin by
comparison to the established marker CA125. Gynecol Oncol.
125:65–69. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Dorigo O and Berek JS: Personalizing CA125
levels for ovarian cancer screening. Cancer Prev Res (Phila).
4:1356–1359. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Goel HL and Mercurio AM: VEGF targets the
tumour cell. Nat Rev Cancer. 13:871–882. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Vempati P, Popel AS and MacGabhann F:
Formation of VEGF isoform-specific spatial distributions governing
angiogenesis: Computational analysis. BMC Syst Biol. 5:592011.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wada H, Ura S, Kitaoka S, Satoh-Asahara N,
Horie T, Ono K, Takaya T, Takanabe-Mori R, Akao M, Abe M, et al:
Distinct characteristics of circulating vascular endothelial growth
factor-A and C levels in human subjects. PLoS One. 6:e293512011.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wang X, Chen X, Fang J and Yang C:
Overexpression of both VEGF-A and VEGF-C in gastric cancer
correlates with prognosis, and silencing of both is effective to
inhibit cancer growth. Int J Clin Exp Pathol. 6:586–597.
2013.PubMed/NCBI
|
|
19
|
Li L, Wang L, Zhang W, Tang B, Zhang J,
Song H, Yao D, Tang Y, Chen X, Yang Z, et al: Correlation of serum
VEGF levels with clinical stage, therapy efficacy, tumor metastasis
and patient survival in ovarian cancer. Anticancer Res.
24:1973–1979. 2004.PubMed/NCBI
|
|
20
|
Lan Z, Fu D, Yu X and Xi M: Diagnostic
values of osteopontin combined with CA125 for ovarian cancer: A
meta-analysis. Fam Cancer. 15:221–230. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ramchandani D and Weber GF: Interactions
between osteopontin and vascular endothelial growth factor:
Implications for cancer. Biochim Biophys Acta. 1855:202–222.
2015.PubMed/NCBI
|
|
22
|
Wang YD, Chen H, Liu HQ and Hao M:
Correlation between ovarian neoplasm and serum levels of
osteopontin: A meta-analysis. Tumour Biol. 35:11799–11808. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Rao G, Wang H, Li B, Huang L, Xue D, Wang
X, Jin H, Wang J, Zhu Y, Lu Y, et al: Reciprocal interactions
between tumor-associated macrophages and CD44-positive cancer cells
via osteopontin/CD44 promote tumorigenicity in colorectal cancer.
Clin Cancer Res. 19:785–797. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kim JH, Skates SJ, Uede T, Wong KK,
Schorge JO, Feltmate CM, Berkowitz RS, Cramer DW and Mok SC:
Osteopontin as a potential diagnostic biomarker for ovarian cancer.
JAMA. 287:1671–1679. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Tilli TM, Franco VF, Robbs BK, Wanderley
JL, da Silva FR, de Mello KD, Viola JP, Weber GF and Gimba ER:
Osteopontin-c splicing isoform contributes to ovarian cancer
progression. Mol Cancer Res. 9:280–293. 2011. View Article : Google Scholar : PubMed/NCBI
|
